Evaluation of prognostic factors in liver-limited metastatic colorectal cancer: A preplanned analysis of the FIRE-1 trial

British Journal of Cancer

Volumn 109, Issue 6, 2013, Pages 1428-1436

  Giessen, C ^a   Fischer Von Weikersthal, L ^b   Laubender, R P ^c,d   Stintzing, S ^a   Modest, D P ^a   Schalhorn, A ^a   Schulz, C ^a   Heinemann, V ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b MVZ Gesundheitszentrum St Marien ^*  (Germany)

^c GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^d UNIVERSITY OF MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE; CARCINOEMBRYONIC ANTIGEN; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; LACTATE DEHYDROGENASE; OXALIPLATIN;

ADULT; AGED; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; CANCER ADJUVANT THERAPY; CANCER PROGNOSIS; COLORECTAL LIVER METASTASIS; FEMALE; HUMAN; KARNOFSKY PERFORMANCE STATUS; LACTATE DEHYDROGENASE BLOOD LEVEL; LEUKOCYTE; LEUKOCYTE COUNT; LIVER RESECTION; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; COLORECTAL NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; SURVIVAL ANALYSIS; YOUNG ADULT;

EID: 84884593703     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2013.475     Document Type: Article

References (31)

1. Adam R, Avisar E, Ariche A, Giachetti S, Azoulay D, Castaing D, Kunstlinger F, Levi F, Bismuth F (2001) Five-year survival following hepatic resection after neoadjuvant therapy for nonresectable colorectal. Ann Surg Oncol 8(4): 347-353.
2. Adam R, Haller DG, Poston G, Raoul JL, Spano JP, Tabernero J, Van Cutsem E (2010) Toward optimized front-line therapeutic strategies in patients with metastatic colorectal cancer-an expert review from the International Congress on Anti-Cancer Treatment (ICACT) 2009. Ann Oncol 21(8): 1579-1584.
3. Alberts SR, Horvath WL, Sternfeld WC, Goldberg RM, Mahoney MR, Dakhil SR, Levitt R, Rowland K, Nair S, Sargent DJ, Donohue JH (2005) Oxaliplatin, fluorouracil, and leucovorin for patients with unresectable liver-only metastases from colorectal cancer: A North Central Cancer Treatment Group phase II study. J Clin Oncol 23(36): 9243-9249.
4. Balkwill F (2004) Cancer and the chemokine network. Nat Rev Cancer 4(7): 540-550.
5. Barone C, Nuzzo G, Cassano A, Basso M, Schinzari G, Giuliante F, D'Argento E, Trigila N, Astone A, Pozzo C (2007) Final analysis of colorectal cancer patients treated with irinotecan and 5-fluorouracil plus folinic acid neoadjuvant chemotherapy for unresectable liver metastases. Br J Cancer 97(8): 1035-1039.
6. Bruera G, Cannita K, Giuliante F, Lanfiuti Baldi P, Vicentini R, Marchetti P, Nuzzo G, Antonucci A, Ficorella C, Ricevuto E (2012) Effectiveness of liver metastasectomies in patients with metastatic colorectal cancer treated with FIr-B/FOx triplet chemotherapy plus bevacizumab. Clin Colorectal Cancer 11(2): 119-126.
7. Chibaudel B, Bonnetain F, Tournigand C, Bengrine-Lefevre L, Teixeira L, Artru P, Desrame J, Larsen AK, Andre T, Louvet C, de Gramont A (2011) Simplified prognostic model in patients with oxaliplatin-based or irinotecan-based first-line chemotherapy for metastatic colorectal cancer: A GERCOR study. Oncologist 16(9): 1228-1238.
8. Desot E, de Mestier L, Volet J, Delmas C, Garcia B, Geoffroy P, Abdelli N, Baule M, Dubroeucq O, Marquis E, Bouche O (2013) Prognostic factors in patients with non resectable metastatic colorectal cancer in the era of targeted biotherapies: Relevance of Kohne's risk classification. Dig Liver Dis 45(4): 330-335.
9. Eigentler TK, Figl A, Krex D, Mohr P, Mauch C, Rass K, Bostroem A, Heese O, Koelbl O, Garbe C, Schadendorf D (2011) Number of metastases, serum lactate dehydrogenase level, and type of treatment are prognostic factors in patients with brain metastases of malignant melanoma. Cancer 117(8): 1697-1703.
10. Fischer von Weikersthal L, Schalhorn A, Stauch M, Quietzsch D, Maubach PA, Lambertz H, Oruzio D, Schlag R, Weigang-Kohler K, Vehling-Kaiser U, Schulze M, Truckenbrodt J, Goebeler M, Mittermuller J, Bosse D, Szukics B, Grundeis M, Zwingers T, Giessen C, Heinemann V (2010) Phase III trial of irinotecan plus infusional 5-fluorouracil/folinic acid versus irinotecan plus oxaliplatin as first-line treatment of advanced colorectal cancer. Eur J Cancer 47(2): 206-214.
11. Folprecht G, Gruenberger T, Bechstein WO, Raab HR, Lordick F, Hartmann JT, Lang H, Frilling A, Stoehlmacher J, Weitz J, Konopke R, Stroszczynski C, Liersch T, Ockert D, Herrmann T, Goekkurt E, Parisi F, Kohne CH (2010) Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: The CELIM randomised phase 2 trial. Lancet Oncol 11(1): 38-47.
12. Fong Y, Fortner J, Sun RL, Brennan MF, Blumgart LH (1999) Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: Analysis of 1001 consecutive cases. Ann Surg 230(3): 309-318. Discussion 318-21.
13. Gerlinger M, Wilson P, Powles T, Shamash J (2010) Elevated LDH predicts poor outcome of recurrent germ cell tumours treated with dose dense chemotherapy. Eur J Cancer 46(16): 2913-2918.
14. Ishibashi K, Okada N, Tajima Y, Amano K, Hatano S, Kuwabara K, Sobajima J, Ishiguro T, Ohsawa T, Kumamoto K, Kumagai Y, Baba H, Tsuji Y, Haga N, Ishida H (2012) [Predictive value of Kohne's index on the efficacy of FOLFIRI regimen in the treatment of unresectable liver metastatsis of colorectal cancer]. Gan To Kagaku Ryoho 39(12): 2182-2184.
15. Kohne CH, Cunningham D, Di Costanzo F, Glimelius B, Blijham G, Aranda E, Scheithauer W, Rougier P, Palmer M, Wils J, Baron B, Pignatti F, Schoffski P, Micheel S, Hecker H (2002) Clinical determinants of survival in patients with 5-fluorouracil-based treatment for metastatic colorectal cancer: Results of a multivariate analysis of 3825 patients. Ann Oncol 13(2): 308-317.
16. Kopetz S, Chang GJ, Overman MJ, Eng C, Sargent DJ, Larson DW, Grothey A, Vauthey JN, Nagorney DM, McWilliams RR (2009) Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy. J Clin Oncol 27(22): 3677-3683.
17. Koukourakis MI, Giatromanolaki A, Simopoulos C, Polychronidis A, Sivridis E (2005) Lactate dehydrogenase 5 (LDH5) relates to up-regulated hypoxia inducible factor pathway and metastasis in colorectal cancer. Clin Exp Metastasis 22(1): 25-30.
18. Mekenkamp LJ, Koopman M, Teerenstra S, van Krieken JH, Mol L, Nagtegaal ID, Punt CJ (2010) Clinicopathological features and outcome in advanced colorectal cancer patients with synchronous vs metachronous metastases. Br J Cancer 103(2): 159-164.
19. Nordlinger B, Guiguet M, Vaillant JC, Balladur P, Boudjema K, Bachellier P, Jaeck D (1996) Surgical resection of colorectal carcinoma metastases to the liver. A prognostic scoring system to improve case selection, based on 1568 patients. Association Francaise de Chirurgie. Cancer 77(7): 1254-1262.
20. Petrelli F, Barni S (2012) Resectability and outcome with anti-EGFR agents in patients with KRAS wild-type colorectal liver-limited metastases: A meta-analysis. Int J Colorectal Dis 27(8): 997-1004.
21. Power DG, Kemeny NE (2011) Chemotherapy for the conversion of unresectable colorectal cancer liver metastases to resection. Crit Rev Oncol Hematol 79(3): 251-264.
22. Proctor MJ, McMillan DC, Morrison DS, Fletcher CD, Horgan PG, Clarke SJ (2012) A derived neutrophil to lymphocyte ratio predicts survival in patients with cancer. Br J Cancer 107(4): 695-699.
23. Rees M, Tekkis PP, Welsh FK, O'Rourke T, John TG (2008) Evaluation of long-term survival after hepatic resection for metastatic colorectal cancer: A multifactorial model of 929 patients. Ann Surg 247(1): 125-135.
24. Sanoff HK, Sargent DJ, Campbell ME, Morton RF, Fuchs CS, Ramanathan RK, Williamson SK, Findlay BP, Pitot HC, Goldberg RM (2008) Five-year data and prognostic factor analysis of oxaliplatin and irinotecan combinations for advanced colorectal cancer: N9741. J Clin Oncol 26(35): 5721-5727.
25. Schmoll HJ, Van Cutsem E, Stein A, Valentini V, Glimelius B, Haustermans K, Nordlinger B, van de Velde CJ, Balmana J, Regula J, Nagtegaal ID, Beets-Tan RG, Arnold D, Ciardiello F, Hoff P, Kerr D, Kohne CH, Labianca R, Price T, Scheithauer W, Sobrero A, Tabernero J, Aderka D, Barroso S, Bodoky G, Douillard JY, El Ghazaly H, Gallardo J, Garin A, Glynne-Jones R, Jordan K, Meshcheryakov A, Papamichail D, Pfeiffer P, Souglakos I, Turhal S, Cervantes A (2012) ESMO Consensus Guidelines for management of patients with colon and rectal cancer. a personalized approach to clinical decision making. Ann Oncol 23(10): 2479-2516.
26. Shankar A, Wang JJ, Rochtchina E, Yu MC, Kefford R, Mitchell P (2006) Association between circulating white blood cell count and cancer mortality: A population-based cohort study. Arch Intern Med 166(2): 188-194.
27. Slesser AA, Georgiou P, Brown G, Mudan S, Goldin R, Tekkis P (2013) The tumour biology of synchronous and metachronous colorectal liver metastases: A systematic review. Clin Exp Metastasis 30(4): 457-470.
28. Sorbye H, Kohne CH, Sargent DJ, Glimelius B (2007) Patient characteristics and stratification in medical treatment studies for metastatic colorectal cancer: A proposal for standardization of patient characteristic reporting and stratification. Ann Oncol 18(10): 1666-1672.
29. Tas F, Aykan F, Alici S, Kaytan E, Aydiner A, Topuz E (2001) Prognostic factors in pancreatic carcinoma: Serum LDH levels predict survival in metastatic disease. Am J Clin Oncol 24(6): 547-550.
30. Van Cutsem E, Bokemeyer C, Heeger S, Sartorius U, Rougier P, Kohne C (2011) Outcome according to metastatic site in patients with KRAS wildtype tumors: Analysis from the CRYSTAL and OPUS studies. ASCO Meet Abstracts. Abstracts 29(4-suppl): 472.
31. Vigano L, Russolillo N, Ferrero A, Langella S, Sperti E, Capussotti L (2012) Evolution of long-term outcome of liver resection for colorectal metastases: Analysis of actual 5-year survival rates over two decades. Ann Surg Oncol 19(6): 2035-2044.